Laurina

Desogestrel/Ethinylestradiol, the active ingredient in Laurina, is a combined oral contraceptive presented as a tablet for oral use. It works by suppressing ovulation and altering cervical mucus, providing reliable, reversible contraception for women of childbearing age seeking to prevent pregnancy.

GNH USA supplies Laurina as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured product availability across global markets. The company adheres to stringent regulatory standards and provides comprehensive logistics support for timely delivery worldwide.

Laurina, a combined oral contraceptive, acts on the hormonal regulation pathway to prevent pregnancy. Contraception: provides reliable prevention of pregnancy by inhibiting ovulation and altering cervical mucus. Pregnancy prevention: offers a reversible, hormone‑based method for women seeking to avoid conception. Menstrual cycle regulation: can help achieve more predictable bleeding patterns and reduce dysmenorrhea in users.

Laurina may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Breast tenderness - Headache - Weight gain - Mood changes - Spotting between periods

Serious or Rare Side Effects: - Venous thromboembolism (deep vein thrombosis, pulmonary embolism) - Arterial thrombosis (stroke, myocardial infarction) - Severe hypertension - Liver dysfunction or cholestasis - Allergic reactions including anaphylaxis - Visual disturbances or ocular migraines

Before prescribing Laurina, clinicians should consider several precautionary measures to ensure patient safety. Cardiovascular risk assessment: evaluate history of thrombosis, smoking, hypertension, and age over 35. Estrogen‑sensitive conditions: avoid in patients with known breast, uterine, or ovarian cancer. Liver function monitoring: use with caution in hepatic impairment and discontinue if severe liver disease develops. Medication review: assess concomitant drugs that may reduce contraceptive efficacy or increase hormone levels. Pregnancy status confirmation: ensure patient is not pregnant before initiating therapy. Store at ambient temperature: keep tablets in original packaging, protect from moisture and heat, and store below 25 °C.

Laurina can interact with other medicines, affecting its effectiveness or safety.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): may markedly reduce hormonal levels and contraceptive efficacy. - Rifampicin and other potent CYP3A4 inducers: can decrease plasma concentrations of desogestrel and ethinylestradiol. - St. John’s wort: herbal inducer that may compromise contraceptive protection.

Moderate Interactions (Monitor Closely): - Antifungal agents (e.g., fluconazole, itraconazole): may increase estrogen levels, raising risk of side effects. - Protease inhibitors (e.g., ritonavir): can alter hormone metabolism, requiring monitoring. - Diuretics (e.g., thiazides): may affect fluid balance and blood pressure, necessitating observation.